Announcement • Apr 27
KPJ Healthcare Berhad, Annual General Meeting, Jun 16, 2026 KPJ Healthcare Berhad, Annual General Meeting, Jun 16, 2026, at 10:00 Singapore Standard Time. Location: the weave, level 8a, menara kpj, 238, jalan tun razak, 50400 kuala lumpur, Malaysia Upcoming Dividend • Mar 20
Upcoming dividend of RM0.013 per share Eligible shareholders must have bought the stock before 27 March 2026. Payment date: 17 April 2026. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Malaysian dividend payers (5.5%). In line with average of industry peers (1.2%). Price Target Changed • Mar 03
Price target increased by 7.6% to RM3.16 Up from RM2.94, the current price target is an average from 16 analysts. New target price is approximately in line with last closing price of RM3.20. Stock is up 20% over the past year. The company is forecast to post earnings per share of RM0.092 for next year compared to RM0.084 last year. Declared Dividend • Mar 02
Fourth quarter dividend increased to RM0.013 Dividend of RM0.013 is 17% higher than last year. Ex-date: 27th March 2026 Payment date: 17th April 2026 Dividend yield will be 1.5%, which is higher than the industry average of 1.3%. Sustainability & Growth Dividend is well covered by both earnings (49% earnings payout ratio) and cash flows (29% cash payout ratio). The dividend has increased by an average of 9.0% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 27
Full year 2025 earnings released: EPS: RM0.084 (vs RM0.076 in FY 2024) Full year 2025 results: EPS: RM0.084 (up from RM0.076 in FY 2024). Revenue: RM4.26b (up 8.6% from FY 2024). Net income: RM366.0m (up 11% from FY 2024). Profit margin: 8.6% (up from 8.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Nov 24
Third quarter dividend increased to RM0.012 Dividend of RM0.012 is 7.0% higher than last year. Ex-date: 5th December 2025 Payment date: 23rd December 2025 Dividend yield will be 1.6%, which is higher than the industry average of 1.3%. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (36% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 20% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Nov 23
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: EPS: RM0.022 (up from RM0.02 in 3Q 2024). Revenue: RM1.12b (up 8.1% from 3Q 2024). Net income: RM93.9m (up 9.2% from 3Q 2024). Profit margin: 8.4% (up from 8.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 4.3%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 22
KPJ Healthcare Berhad Approves Interim Single Tier Dividend in Respect of Financial Year Ending 31 December 2025, Payable on 23 December 2025 KPJ Healthcare Berhad Directors had on 21 November 2025, approved an interim single tier dividend of 1.23 sen in respect of financial year ending 31 December 2025 amounting to MYR 53.7 million. The proposed dividend will be paid on 23 December 2025 to shareholders registered at the close of business on 5 December 2025. Buy Or Sell Opportunity • Nov 05
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.1% to RM2.74. The fair value is estimated to be RM3.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 21% in the next 2 years. Buy Or Sell Opportunity • Oct 02
Now 21% undervalued Over the last 90 days, the stock has risen 2.6% to RM2.76. The fair value is estimated to be RM3.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 21% in the next 2 years. Reported Earnings • Aug 31
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: RM0.019 (up from RM0.018 in 2Q 2024). Revenue: RM1.02b (up 11% from 2Q 2024). Net income: RM82.0m (up 5.5% from 2Q 2024). Profit margin: 8.0% (down from 8.4% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 87%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Aug 30
Second quarter dividend of RM0.011 announced Shareholders will receive a dividend of RM0.011. Ex-date: 19th September 2025 Payment date: 10th October 2025 Dividend yield will be 1.6%, which is higher than the industry average of 1.3%. Sustainability & Growth Dividend is covered by both earnings (54% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 7.6% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Major Estimate Revision • Aug 29
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from RM4.26b to RM4.18b. EPS estimate also fell from RM0.088 per share to RM0.078 per share. Net income forecast to grow 7.4% next year vs 17% growth forecast for Healthcare industry in Malaysia. Consensus price target broadly unchanged at RM2.93. Share price fell 5.1% to RM2.60 over the past week. Announcement • May 31
KPJ Healthcare Berhad Announces Single Tier Interim Dividend, Payable on 11 July 2025 KPJ Healthcare Berhad announced 0.80 sen single tier interim dividend per ordinary share. The above Company's securities will be traded and quoted "Ex - Dividend” as from: 19 June 2025. The last date of lodgment: 20 June 2025. Date Payable: 11 July 2025. Buy Or Sell Opportunity • May 30
Now 23% undervalued Over the last 90 days, the stock has risen 15% to RM2.72. The fair value is estimated to be RM3.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 39%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 32% in the next 2 years. Reported Earnings • Apr 30
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: RM0.076 (up from RM0.065 in FY 2023). Revenue: RM3.92b (up 15% from FY 2023). Net income: RM331.1m (up 18% from FY 2023). Profit margin: 8.4% (up from 8.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 45% per year. Announcement • Apr 25
KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2025 KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2025, at 10:00 Singapore Standard Time. Location: level 8a, menara kpj, 238, jalan tun razak, 50400 kuala lumpur, Malaysia Upcoming Dividend • Mar 17
Upcoming dividend of RM0.011 per share Eligible shareholders must have bought the stock before 24 March 2025. Payment date: 18 April 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Malaysian dividend payers (5.6%). In line with average of industry peers (1.5%). Buy Or Sell Opportunity • Mar 11
Now 25% undervalued Over the last 90 days, the stock has risen 14% to RM2.59. The fair value is estimated to be RM3.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 47%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to RM2.76, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 20x in the Healthcare industry in Malaysia. Total returns to shareholders of 199% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at RM3.44 per share. Price Target Changed • Mar 04
Price target increased by 7.1% to RM2.78 Up from RM2.59, the current price target is an average from 16 analysts. New target price is approximately in line with last closing price of RM2.66. Stock is up 59% over the past year. The company is forecast to post earnings per share of RM0.088 for next year compared to RM0.076 last year. Announcement • Mar 03
KPJ Healthcare Berhad to Report Q4, 2024 Results on Feb 28, 2025 KPJ Healthcare Berhad announced that they will report Q4, 2024 results on Feb 28, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: RM0.076 (up from RM0.065 in FY 2023). Revenue: RM3.92b (up 15% from FY 2023). Net income: RM331.1m (up 18% from FY 2023). Profit margin: 8.4% (up from 8.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Mar 01
Consensus EPS estimates increase by 20% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from RM0.079 to RM0.095. Revenue forecast steady at RM4.15b. Net income forecast to grow 33% next year vs 15% growth forecast for Healthcare industry in Malaysia. Consensus price target broadly unchanged at RM2.60. Share price fell 6.7% to RM2.37 over the past week. Announcement • Feb 28
KPJ Healthcare Berhad Announces Single Tier Special Dividend Per Ordinary Share for the Financial Year Ended 31 December 2025, Payable on 18 April 2025 KPJ Healthcare Berhad announced 0.10 sen single tier special dividend per ordinary share for the financial Year ended 31 December 2025. Ex-Date is 24 March 2025. Payment Date is 18 April 2025. Entitlement date is 25 March 2025. Announcement • Feb 18
Kpj Healthcare Berhad Announces Resignation of Encik Mohamed Ridza Bin Mohamed Abdulla as Independent and Non Executive Director KPJ Healthcare Berhad announced resignation of Encik Mohamed Ridza Bin Mohamed Abdulla as Independent and Non Executive Director. Date of change is February 18, 2025. Age is 55. Reason is To focus on other commitments. Price Target Changed • Nov 26
Price target increased by 9.3% to RM2.37 Up from RM2.17, the current price target is an average from 14 analysts. New target price is approximately in line with last closing price of RM2.40. Stock is up 85% over the past year. The company is forecast to post earnings per share of RM0.069 for next year compared to RM0.065 last year. Reported Earnings • Nov 26
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: RM0.02 (down from RM0.021 in 3Q 2023). Revenue: RM1.03b (up 12% from 3Q 2023). Net income: RM86.0m (down 4.7% from 3Q 2023). Profit margin: 8.3% (down from 9.8% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Declared Dividend • Aug 30
Second quarter dividend of RM0.01 announced Shareholders will receive a dividend of RM0.01. Ex-date: 12th September 2024 Payment date: 4th October 2024 Dividend yield will be 2.2%, which is higher than the industry average of 1.3%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (37% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Aug 29
KPJ Healthcare Berhad to Report Q2, 2024 Results on Aug 28, 2024 KPJ Healthcare Berhad announced that they will report Q2, 2024 results on Aug 28, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings: Revenues exceed analyst expectations Second quarter 2024 results: Revenue: RM930.6m (up 16% from 2Q 2023). Net income: RM77.6m (up 65% from 2Q 2023). Profit margin: 8.3% (up from 5.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.6%. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in Malaysia. Price Target Changed • Jun 15
Price target increased by 7.4% to RM1.93 Up from RM1.80, the current price target is an average from 13 analysts. New target price is approximately in line with last closing price of RM1.96. Stock is up 68% over the past year. The company is forecast to post earnings per share of RM0.065 for next year compared to RM0.065 last year. Declared Dividend • May 29
First quarter dividend of RM0.01 announced Shareholders will receive a dividend of RM0.01. Ex-date: 13th June 2024 Payment date: 5th July 2024 Dividend yield will be 2.1%, which is higher than the industry average of 1.3%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 28
First quarter 2024 earnings: EPS misses analyst expectations First quarter 2024 results: EPS: RM0.017 (up from RM0.012 in 1Q 2023). Revenue: RM908.0m (up 9.5% from 1Q 2023). Net income: RM75.8m (up 46% from 1Q 2023). Profit margin: 8.4% (up from 6.3% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Announcement • May 11
KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2024 KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2024, at 11:00 Singapore Standard Time. Location: ballroom 1 and 2, level 1, sime darby convention centre, 1a, jalan bukit kiara 1, bukit kiara, 60000 kuala lumpur, Malaysia Announcement • Mar 15
KPJ Healthcare Berhad Announces Resignation of Md Arif Bin Mahmood as Non Independent and Non Executive Chairman, Effective April 1, 2024 KPJ Healthcare Berhad announced resignation of Md Arif Bin Mahmood as Non Independent and Non Executive Chairman. Age: 61. Nationality: Malaysia. Date of change: 01 Apr. 2024. Reason To pursue other interests.Remarks: YBhg. Datuk Md Arif Bin Mahmood will step down as Non-Independent Non-Executive Chairman of the Company with effect from 1 April 2024. His last day with the Company will be on 31 March 2024. The announcement regarding the appointment of the new Chairman will be made in due course. Price Target Changed • Feb 19
Price target increased by 8.3% to RM1.72 Up from RM1.59, the current price target is an average from 13 analysts. New target price is 6.9% above last closing price of RM1.61. Stock is up 40% over the past year. The company is forecast to post earnings per share of RM0.062 for next year compared to RM0.065 last year. Reported Earnings • Feb 17
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: RM0.065 (up from RM0.04 in FY 2022). Revenue: RM3.42b (up 17% from FY 2022). Net income: RM281.3m (up 64% from FY 2022). Profit margin: 8.2% (up from 5.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.5%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 05
Upcoming dividend of RM0.013 per share at 3.0% yield Eligible shareholders must have bought the stock before 12 December 2023. Payment date: 28 December 2023. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Malaysian dividend payers (5.1%). Higher than average of industry peers (1.4%). Price Target Changed • Nov 30
Price target increased by 8.6% to RM1.48 Up from RM1.37, the current price target is an average from 12 analysts. New target price is 11% above last closing price of RM1.34. Stock is up 41% over the past year. The company is forecast to post earnings per share of RM0.05 for next year compared to RM0.04 last year. Reported Earnings • Nov 29
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: RM0.021 (up from RM0.013 in 3Q 2022). Revenue: RM925.4m (up 14% from 3Q 2022). Net income: RM90.3m (up 66% from 3Q 2022). Profit margin: 9.8% (up from 6.7% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.8%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Nov 29
KPJ Healthcare Berhad Announces Single Tier Special Dividend for the Financial Year Ending 31 December 2023 KPJ Healthcare Berhad announced 0.25 sen single tier special dividend per ordinary share for the financial year ending 31 December 2023. Ex-Date: 12 December 2023. Payment Date: 28 December 2023. Announcement • Sep 02
KPJ Healthcare Berhad Announces Appointment of Keh Ching Tyng as Joint Secretary KPJ Healthcare Berhad announced appointment of Mr. Keh Ching Tyng as Joint Secretary. Date Of Change 01 Sep 2023. Reported Earnings • Aug 30
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: RM0.011 (up from RM0.006 in 2Q 2022). Revenue: RM799.5m (up 13% from 2Q 2022). Net income: RM46.9m (up 73% from 2Q 2022). Profit margin: 5.9% (up from 3.8% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 91%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year. Announcement • Jun 01
KPJ Healthcare Berhad Declares Interim Dividend for the Year Ended December 31, 2023, Payable on July 4, 2023 KPJ Healthcare Berhad announced 0.65 sen single tier interim dividend per ordinary share for the year ended December 31, 2023. Ex-Date is June 16, 2023. Entitlement date is June 19, 2023. Payment date is July 4, 2023. Reported Earnings • May 31
First quarter 2023 earnings: EPS exceeds analyst expectations First quarter 2023 results: EPS: RM0.012 (up from RM0.005 in 1Q 2022). Revenue: RM829.0m (up 27% from 1Q 2022). Net income: RM51.9m (up 134% from 1Q 2022). Profit margin: 6.3% (up from 3.4% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Buying Opportunity • May 12
Now 22% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be RM1.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings is also forecast to grow by 14% per annum over the same time period. Reported Earnings • Apr 30
Full year 2022 earnings released: EPS: RM0.04 (vs RM0.013 in FY 2021) Full year 2022 results: EPS: RM0.04 (up from RM0.013 in FY 2021). Revenue: RM2.92b (up 13% from FY 2021). Net income: RM172.0m (up 214% from FY 2021). Profit margin: 5.9% (up from 2.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Buying Opportunity • Apr 26
Now 23% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be RM1.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings is also forecast to grow by 14% per annum over the same time period. Buying Opportunity • Apr 07
Now 22% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be RM1.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings is also forecast to grow by 14% per annum over the same time period. Buying Opportunity • Mar 08
Now 21% undervalued Over the last 90 days, the stock is up 19%. The fair value is estimated to be RM1.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has declined by 29%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings is also forecast to grow by 14% per annum over the same time period. Major Estimate Revision • Feb 24
Consensus EPS estimates increase by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from RM3.13b to RM3.20b. EPS estimate increased from RM0.039 to RM0.048 per share. Net income forecast to grow 24% next year vs 5.1% growth forecast for Healthcare industry in Malaysia. Consensus price target up from RM1.14 to RM1.27. Share price was steady at RM1.08 over the past week. Price Target Changed • Feb 21
Price target increased by 8.7% to RM1.23 Up from RM1.14, the current price target is an average from 13 analysts. New target price is 13% above last closing price of RM1.09. Stock is up 3.8% over the past year. The company is forecast to post earnings per share of RM0.048 for next year compared to RM0.04 last year. Reported Earnings • Feb 18
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: RM0.04 (up from RM0.012 in FY 2021). Revenue: RM2.92b (up 11% from FY 2021). Net income: RM172.0m (up 237% from FY 2021). Profit margin: 5.9% (up from 1.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 6.6% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in Malaysia. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Feb 18
KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year End December 31, 2023, Payable on April 14, 2023 KPJ Healthcare Berhad announced 0.6 sen single tier interim dividend per ordinary share for the financial year end December 31, 2023, payable on April 14, 2023, Ex-Date March 30, 2023. Entitlement date is March 21, 2022. 
